SG10201600077RA - Combination - Google Patents

Combination

Info

Publication number
SG10201600077RA
SG10201600077RA SG10201600077RA SG10201600077RA SG10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA SG 10201600077R A SG10201600077R A SG 10201600077RA
Authority
SG
Singapore
Prior art keywords
combination
Prior art date
Application number
SG10201600077RA
Other languages
English (en)
Inventor
Rakesh Kumar
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of SG10201600077RA publication Critical patent/SG10201600077RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/005Enzyme inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG10201600077RA 2011-01-11 2012-01-11 Combination SG10201600077RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161431508P 2011-01-11 2011-01-11

Publications (1)

Publication Number Publication Date
SG10201600077RA true SG10201600077RA (en) 2016-02-26

Family

ID=46507420

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201600077RA SG10201600077RA (en) 2011-01-11 2012-01-11 Combination
SG2013043856A SG191724A1 (en) 2011-01-11 2012-01-11 Combination

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2013043856A SG191724A1 (en) 2011-01-11 2012-01-11 Combination

Country Status (15)

Country Link
US (6) US20130288984A1 (enExample)
EP (1) EP2663189B1 (enExample)
JP (1) JP6100700B2 (enExample)
KR (1) KR20140053836A (enExample)
CN (1) CN103298345B (enExample)
AU (1) AU2012205601B2 (enExample)
BR (1) BR112013017722A2 (enExample)
CA (1) CA2824201A1 (enExample)
EA (1) EA029000B1 (enExample)
ES (1) ES2689760T3 (enExample)
IL (1) IL227097B (enExample)
MX (1) MX356704B (enExample)
SG (2) SG10201600077RA (enExample)
WO (1) WO2012097021A1 (enExample)
ZA (1) ZA201304139B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014330779A1 (en) * 2013-10-01 2016-04-07 Novartis Ag Combination
EP3065549A4 (en) * 2013-11-07 2017-05-24 Deciphera Pharmaceuticals, LLC Methods for inhibiting tie2 kinase useful in the treatment of cancer
EP3746059B1 (en) 2018-01-31 2026-03-04 Deciphera Pharmaceuticals, LLC Combination therapy for the treatment of gastrointestinal stromal tumors
AU2019216351B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc Combination therapy for the treatment of mastocytosis
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4013412T3 (fi) 2019-08-12 2026-03-24 Deciphera Pharmaceuticals Llc Ripretinibi ruoansulatuskanavan stroomakasvaimien hoitoon
AU2020419197B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
PL4084779T3 (pl) 2019-12-30 2025-02-24 Deciphera Pharmaceuticals, Llc Kompozycje 1-(4-bromo-5-(1-etylo-7-(metyloamino)-2-okso-1,2-dihydro-1,6-naftyrydyn-3-ylo)-2-fluorofenylo)-3-fenylomocznika
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6328590B1 (en) 2000-07-20 2001-12-11 Emc Corporation Methods and apparatus for controlling attachment of an electronic module with a circuit board connector
CA2560691A1 (en) * 2004-03-24 2005-10-13 Abbott Laboratories Tricyclic pyrazole kinase inhibitors
CA2584246C (en) 2004-10-13 2011-08-09 Pharmacia & Upjohn Company Llc Crystalline forms of 3-[5-chloro-4-[(2,4-difluorobenzyl)oxy]-6-oxopyrimidin-1(6h)-yl]-n-(2-hydroxyethyl)-4-methylbenzamide
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
JP2009506069A (ja) * 2005-08-26 2009-02-12 ブレインセルス,インコーポレイティド ムスカリン性受容体調節による神経発生
EP1840114A1 (en) 2006-03-30 2007-10-03 LTB4 Sweden AB Crystalline Leukotriene B4
WO2007115286A2 (en) 2006-04-05 2007-10-11 Novartis Ag. Combinations of therapeutic agents for treating cancer
WO2007122686A1 (ja) 2006-04-14 2007-11-01 Eisai R & D Management Co., Ltd. ベンズイミダゾール化合物
PL2061561T3 (pl) 2006-08-25 2013-12-31 Janssen Oncology Inc Kompozycje do leczenia raka
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
JP4299327B2 (ja) 2006-08-31 2009-07-22 トヨタ自動車株式会社 可変バルブタイミング装置
WO2008094321A2 (en) 2006-10-04 2008-08-07 Universtiy Of South Florida Akt sensitization of cancer cells
PE20080859A1 (es) 2006-10-13 2008-09-04 Basf Ag Hidratos de 2-cloro-5-[3,6-dihidro-3-metil-2,6-dioxo-4-(trifluorometil)-1-(2h)-pirimidinil]-4-fluor-n-[[metil(1-metiletil)amino]sulfonil]benzamida
AR064010A1 (es) * 2006-12-06 2009-03-04 Merck & Co Inc Inhibidores de la actividad de la akt
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
BRPI0818533B8 (pt) 2007-10-11 2021-05-25 Astrazeneca Ab composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
WO2009067453A1 (en) * 2007-11-19 2009-05-28 Syndax Pharmaceuticals, Inc. Combinations of hdac inhibitors and proteasome inhibitors
DE102008044901A1 (de) 2008-08-29 2010-03-04 Siemens Aktiengesellschaft Verfahren und Vorrichtung zur Auswahl eines Bestrahlungsplans sowie Bestrahlungsanlage
CA2750565C (en) 2009-01-30 2015-10-20 Glaxosmithkline Llc Crystalline n-{(1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
MA33451B1 (fr) 2009-06-26 2012-07-03 Novartis Ag Dérivés d'imidazolidin-2-one 1,3-disubstitués en tant qu'inhibiteurs de cyp 17
BR112012008274A2 (pt) 2009-10-08 2015-09-22 Glaxosmithkline Llc combinação
ES2620644T3 (es) 2011-04-01 2017-06-29 Genentech, Inc. Combinaciones de compuestos inhibidores de AKT y agentes quimioterapéuticos, y métodos de uso
EP2704699A1 (en) 2011-05-03 2014-03-12 University of Rochester Methods for treating prostate cancer
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
JP6091510B2 (ja) 2011-10-10 2017-03-08 ザック システム 17−置換ステロイドの製造方法
PT2785349T (pt) 2011-11-30 2019-12-11 Astrazeneca Ab Tratamento combinado de cancro
WO2013184572A1 (en) 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
RU2016116789A (ru) 2013-10-01 2017-11-09 Новартис Аг Комбинация энзалутамида и афурезертиба для лечения рака

Also Published As

Publication number Publication date
US10449226B2 (en) 2019-10-22
EP2663189B1 (en) 2018-07-04
MX2013008074A (es) 2013-08-09
US20130288984A1 (en) 2013-10-31
ES2689760T3 (es) 2018-11-15
JP6100700B2 (ja) 2017-03-22
JP2014507412A (ja) 2014-03-27
AU2012205601B2 (en) 2016-03-24
CN103298345A (zh) 2013-09-11
CA2824201A1 (en) 2012-07-19
ZA201304139B (en) 2014-02-26
IL227097B (en) 2018-02-28
US20170100449A1 (en) 2017-04-13
SG191724A1 (en) 2013-08-30
WO2012097021A1 (en) 2012-07-19
CN103298345B (zh) 2016-12-14
EP2663189A1 (en) 2013-11-20
EP2663189A4 (en) 2014-06-11
US20160022641A1 (en) 2016-01-28
MX356704B (es) 2018-06-11
EA201391027A1 (ru) 2014-01-30
AU2012205601A1 (en) 2013-08-01
KR20140053836A (ko) 2014-05-08
EA029000B1 (ru) 2018-01-31
US20160375086A1 (en) 2016-12-29
US20150119337A1 (en) 2015-04-30
BR112013017722A2 (pt) 2016-07-12
US20120258933A1 (en) 2012-10-11

Similar Documents

Publication Publication Date Title
DK3798230T3 (en) Terapeutiske antistoffer
DK2691417T4 (en) Antistof fc-varianter
EP2755962A4 (en) AZAINDAZOLES
ZA201304866B (en) Colonoscopy-preparation
ZA201304139B (en) Combination
PL2606715T3 (pl) Kombinacja prasująco-owijająca
SG10201606981QA (en) 18f-saccharide-folates
GB201117693D0 (en) Combination
GB201116007D0 (en) Combination
GB201121105D0 (en) Combination
GB201106339D0 (en) Combination
GB201101204D0 (en) Swiftnut
GB201108614D0 (en) CarryEase
GB201112150D0 (en) Kerbeye
GB201112879D0 (en) FatigueEEG
GB201107258D0 (en) Cycloptical
GB201104838D0 (en) Thermo-symbiotic-gaming
GB201109856D0 (en) Corcost 345-33
GB201110401D0 (en) BuggyBeams
GB201113286D0 (en) Kh-1856hpp
GB201111981D0 (en) Welliebag
GB201122051D0 (en) Polyester-II
GB201101772D0 (en) Hat-Pack
GB201106857D0 (en) Laptopkey
GB201107154D0 (en) Corcost-zz300